- Home
- SANA
as 12-20-2024 4:00pm EST
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 522.4M | IPO Year: | 2021 |
| Target Price: | $11.50 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.55 - $12.00 | Next Earning Date: | 11-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Sana Biotechnology Inc. (SANA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mulligan Richard | SANA | Director | Sep 24 '24 | Sell | $3.99 | 300,000 | $1,195,740.00 | 2,848,121 |
Latest Sana Biotechnology Inc. News
SANA Breaking Stock News: Dive into SANA Ticker-Specific Updates for Smart Investing
MT Newswires
20 days ago
Sana Biotechnology's SC291 Gets FDA Fast Track Designation for Systemic Lupus Erythematosus
GlobeNewswire
20 days ago
Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus
GlobeNewswire
a month ago
Sana Biotechnology to Present at December 2024 Investor Conferences
Zacks
a month ago
Here's Why Sana (SANA) Could be Great Choice for a Bottom Fisher
Zacks
a month ago
Down -24.69% in 4 Weeks, Here's Why Sana (SANA) Looks Ripe for a Turnaround
Associated Press Finance
a month ago
Sana: Q3 Earnings Snapshot
GlobeNewswire
a month ago
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates
MT Newswires
2 months ago
JMP Securities Downgrades Sana Biotechnology to Market Perform
Compare SANA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SANA Sana Biotechnology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.